Recursion to Participate in Upcoming Investor Conferences
03 juin 2024 09h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 mai 2024 08h21 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...
Recursion to Participate in Upcoming Investor Conferences
01 mai 2024 08h01 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conference
02 avr. 2024 08h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 mars 2024 07h30 HE
|
Evaxion Biotech
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes...
Recursion to Participate in Upcoming Investor Conferences
01 mars 2024 07h59 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
24 janv. 2024 03h00 HE
|
IMU Biosciences
Board strengthened with appointments of Tim Haines (Abingworth) as Non-executive Chair and Dr Oliver Nussbaumer (co-founder of GammaDelta Therapeutics and Adaptate Biotherapeutics) and Dr Inga Deakin...
Leading TechBio Investment Firm ARTIS Ventures Announces 2023 Class of Healthcare and Life Sciences Fellows
12 janv. 2024 12h00 HE
|
ARTIS Ventures
San Francisco, CA, Jan. 12, 2024 (GLOBE NEWSWIRE) -- ARTIS Ventures, a leading venture firm pioneering investments in the TechBio space, today announced its newest class of AV Fellows. Selected from...
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
26 juin 2023 11h48 HE
|
Recursion Pharmaceuticals
TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its...
With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures
12 juin 2023 11h00 HE
|
ARTIS Ventures
San Francisco, CA, June 12, 2023 (GLOBE NEWSWIRE) -- Range Biotechnologies (“Range Bio”), a proteomics-focused biotech company that has developed an innovative translational platform to enable...